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This study reviewed the lipid proﬁle of human immunodeﬁciency virus/acquired immuno-
deﬁciency  syndrome (HIV/AIDS) patients in relation to use of antiretroviral therapy (ART),
and  its different classes of drugs. A  total of 190 articles published in peer-reviewed journals
were  retrieved from PubMed and LILACS databases; 88  of them met  the  selection crite-
ria  and were included in the review. Patients with HIV/AIDS without ART presented an
increase  of triglycerides and decreases of total cholesterol, low  density lipoprotein (LDL-c),
and  high density lipoprotein (HDL-c) levels. Distinct ART regimens appear to promote differ-
ent  alterations in lipid metabolism. Protease inhibitors, particularly indinavir and lopinavir,
were  commonly associated with hypercholesterolemia, high LDL-c, low HDL-c, and hyper-
triglyceridemia.  The protease inhibitor atazanavir is apparently associated with a more
advantageous  lipid proﬁle. Some nucleoside reverse-transcriptase inhibitors (didanosine,
stavudine,  and zidovudine) induced lipoatrophy and hypertriglyceridemia, whereas aba-
cavir  increased the  risk of cardiovascular diseases even in the absence of apparent lipid
disorders,  and tenofovir resulted in lower levels of cholesterol and triglycerides. Although
non-nucleoside  reverse-transcriptase inhibitors predisposed to hypertriglyceridemia and
hypercholesterolemia, nevirapine was particularly associated with high HDL-c levels, a
protective factor against cardiovascular diseases. Therefore, the  infection itself, different
classes  of drugs, and some drugs from the same class of ART appear to exert distinct
alterations  in lipid metabolism.
Perﬁl  lipídico  de pacientes  infectados  pelo  HIV  em  relac¸ão  à terapia
antirretroviral:  uma  revisão
Palavras-chave:
Vírus da Imunodeﬁciência Humana
r  e  s u  m o
Este estudo faz uma revisão sobre o  perﬁl lipídico de pacientes com vírus da imunodeﬁ-
ciência  humana/síndrome da imunodeﬁciência adquirida (HIV/AIDS) em relac¸ão  ao uso da
terapia  antirretroviral (TARV), e  suas diferentes classes de fármacos. Um total de 190 artigos
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publicados em revistas indexadas foram selecionados das bases de dados PubMed e LILACS;
88 deles preencheram os critérios de  selec¸ão e foram incluídos nesta revisão. Pacientes
com HIV/AIDS sem uso de  TARV apresentaram aumento de  triglicérides e diminuic¸ão
dos  níveis de colesterol total, lipoproteína de baixa densidade (LDL-c) e lipoproteína de
alta densidade (HDL-c). Distintos regimes de  TARV promoveram diferentes alterac¸ões  no
metabolismo lipídico. Inibidores de protease, particularmente indinavir e lopinavir, foram
comumente associados com hipercolesterolemia, aumento de LDL-c, diminuic¸ão  de  HDL-c
e hipertrigliceridemia. O inibidor de protease atazanavir aparentemente está associado a
menores alterac¸ões  do perﬁl lipídico. Alguns inibidores da transcripitase reversa análogos
de nucleosídeos (didanosina, estavudina e zidovudina), induziram lipoatroﬁa e hiper-
trigliceridemia, enquanto o abacavir aumentou o risco cardiovascular mesmo na  ausência
de aparentes distúrbios lipídicos, e o tenofovir resultou em menores níveis de colesterol e
triglicérides. Embora os inibidores da transcriptase reversa não análogos de nucleosídeos
possam predispor a hipertrigliceridemia e hipercolesterolemia, a  nevirapina, particular-
mente, foi associada a maiores níveis de HDL-c, um fator de protec¸ão  contra doenc¸as
cardiovasculares.  Portanto, a  própria infecc¸ão,  diferentes classes de  fármacos e alguns
fármacos da mesma classe de  TARV podem exercer distintas alterac¸ões  no metabolismo
lipídico.
Introduction
Patients with human immunodeﬁciency virus (HIV)/acquired
immunodeﬁciency syndrome (AIDS) frequently present alter-
ations  in lipid metabolism due to infection with HIV itself,
including elevated serum concentrations of triglycerides and
low  levels of total cholesterol.1 The introduction of antiretro-
viral  therapy (ART) in the mid-1990s led to  substantial
improvement in the prognosis of HIV/AIDS patients, with a
reduction in morbidity and mortality due to opportunistic dis-
eases  and consequent improvement of the patient’s quality of
life.2–7
However, there is evidence that ART is associated with
lipodystrophy syndrome, a  disturbance of lipid metabolism
characterized by insulin resistance, dyslipidemia, and fat
maldistribution, usually presenting as visceral abdominal obe-
sity  and cervical fat pad accumulation (buffalo hump),2,5,7–9
metabolic bone disease (osteopenia and/or osteoporosis), and
lactic  acidosis.5,7,10–12
ART-associated dyslipidemia is characterized by elevated
serum  concentrations of total cholesterol, triglycerides, low
density  lipoprotein (LDL-c), very low-density lipoprotein
(VLDL), and apolipoprotein B (apoB), and low levels of
high  density lipoprotein (HDL-c), constituting an  athero-
genic  lipid proﬁle.13,14 This lipid changes occurs within three
months  of initiating ART, and plateau after six  to nine
months.15
The prevalence of dyslipidemia and other risk factors for
cardiovascular disease is signiﬁcant in  HIV/AIDS patients
receiving ART, ranging from 20% to 80% depending on
the  study design and population investigated.8 These lipid
alterations were  ﬁrst described in  patients who used antiretro-
viral  regimens containing protease inhibitors, but also were
later observed in  patients who  received regimens consisting
of  nucleoside reverse-transcriptase inhibitors (NRTI) and non-
nucleoside reverse-transcriptase inhibitors (NNRTI).16,17
In view of the high prevalence of dyslipidemia and the
increased risk for cardiovascular diseases among patients
with  HIV/AIDS, which is a  matter of concern for public health,
the  present review aimed to describe the  lipid proﬁle of HIV-
infected  patients in  relation to use of ART, and its different
classes  of drugs.
Methods
The PubMed (US National Library of Medicine, National Insti-
tutes  of Health) and LILACS (Literatura Latino-Americana e do
Caribe) databases were searched without restrictions on pub-
lication  year or study design until August 2011. The keywords
“HIV”  [MESH] OR “Acquired Immunodeﬁciency Syndrome”
[MESH] AND “Dyslipidemias” [MESH] were used for search in
the PubMed database, and 169 articles were  retrieved. The
LILACS  database was searched using “HIV and Dislipidemia”,
and  21 articles were retrieved. Thus, 190 articles were  ﬁrst
selected,  but one article appeared in both databases; therefore,
189  articles were selected for this review.
All studies investigating the association between lipid
alterations in HIV/AIDS patients with or without treatment
were  identiﬁed and included in the review. Case report articles
(12  articles from PubMed), articles related to lipid-lowering
drugs (8 articles from PubMed), articles whose full  text could
not  be accessed (35 articles from PubMed and ﬁve from
LILACS), and articles not focusing on lipid alterations in
HIV/AIDS  patients (39 articles from PubMed and nine from
LILACS)  were excluded. 75  articles were thus selected from the
PubMed  database and six articles from the LILACS database.
In  addition, seven studies were identiﬁed in the references
of  these articles and retrieved for relevance, considering that
the  articles were useful to describe the possible metabolic
mechanisms to explain the lipid alterations of the patients.
Therefore, a total of 88 articles were included in  the review
(Fig.  1).
All  the 88 articles were discussed in  this review.
Tables 1  and 3 presented the results of the original articles
(n  = 51) included in this search, excluding previously published
reviews.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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PubMed
LILACS
Keywords: “HIV” [MESH] or “Acquired
Immunodefcency Syndrome” [MESH] and
“Dyslipidemias” [MESH] = 169 articles were
retrieved.
Keywords: “HIV and dislipidemia” = 21 articles
were retrieved.
75 articles
Total = 88
articles were
included in
the review.
6 articles
+ 7 articles
Excluded were articles involving:Excluded were articles involving:
• Case reports (12);
• Articles related to lipid-lowering
drugs (8);
• Articles whose full text could not be
accessed (35);
• Articles not focusing on lipid
alterations in HIV/AIDS patients
(39).
• Articles whose full text could not be
accessed (5);
• Articles not focusing on lipid
alterations in HIV/AIDS patients (9).
Fig. 1 – Research design.
Results  and  discussion
HIV/AIDS  and  lipid  alterations
Lipid alterations in patients with HIV/AIDS caused by the
infection  itself had been reported before the implementation
of ART.1,13 In this respect, serum triglyceride concentrations
were  higher and the levels of total cholesterol, LDL-c and
HDL-c  were  lower in  HIV-seropositive patients receiving no
ART  when compared to uninfected controls.1,18,19 These alter-
ations  were  detected in patients infected with different HIV-1
subtypes.19
Low serum concentrations of HDL-c can be  used as a
marker  of chronic inﬂammatory activity.20 In a cohort study
conducted  in Spain, untreated HIV-infected patients pre-
sented  low HDL-c levels, especially if they had already received
antiretroviral therapy in the past.21 However, HDL-c levels
were  found to be low even in patients receiving ART presenting
adequate  viral suppression and immune reconstitution, a
ﬁnding  that suggests that inﬂammatory activity was  not com-
pletely  controlled.20
Table 1 summarizes the results of the original studies (n = 3)
that  assessed the lipid proﬁle of HIV/AIDS patients without
ART.
Possible  metabolic  mechanisms
Factors that contribute to dyslipidemia in HIV infection
are altered cytokine proﬁle, decreased lipid clearance, and
increased  hepatic synthesis of VLDL.23
Cytokines such as  tumor necrosis factor alpha (TNF-)
and  interleukin-6 (IL-6) appear to promote lipid peroxidation,
besides endothelial and platelet activation, and the produc-
tion  of reactive oxygen species.14
An  increase in serum triglyceride concentrations is
observed in HIV-infected patients as  the disease progresses,
particularly in  the presence of opportunistic infections, possi-
bly  due to  an  increase in  the levels of inﬂammatory cytokines
(TNF- , interleukins, and interferon alpha [IFN- ])22,24 and
steroid hormones.1,18 The lower the CD4+ T lymphocyte
count in peripheral blood, the higher the concentrations of
triglycerides  and the lower the levels of total cholesterol and
LDL-c.1,18 In contrast, low concentrations of HDL-c are found
in  HIV-infected patients, regardless of the CD4+ T lymphocyte
count.18,25
HIV/AIDS,  ART,  and  lipid  alterations
Changes in lipid metabolism associated with ART use have
been  commonly reported in all age groups of HIV-infected
patients.5–7
In relation to the metabolic side effects of ART, children are
more  vulnerable than adults because of their status as growing
organisms and their longer exposure to ART.5
Cross-sectional studies with HIV-infected children and
adolescents receiving ART have shown high frequency
of dyslipidemia, lipodystrophy,26–28 retinol, and b-carotene
deﬁciencies27 and, therefore, high risk for cardiovascular
diseases.28 In a  multicenter study, HIV-infected children
with symptoms of fat redistribution presented adiponectin
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Table 1 – Studies assessing the lipid proﬁle of patients with HIV/AIDS without ART.
Reference Study design and  treatment
duration
Lipid  proﬁle alterations
Fourie et al.
(2010)19
Sub-study from  PURE
HIV+  (n = 300) versus HIV−
(n = 300): 12 years
-  HIV+ versus HIV-: ↓HDL-c (1.23 versus 1.7  mmol/L); ↓LDL-c (2.6 versus
2.8 mmol/L); ↑TG (1.29  versus 1.15 mmol/L), ↑CRP (3.31 versus 2.13 mg/L); ↑IL-6 (4.7
versus 3.72 pg/L)
- HIV-1 subtype C was associated with dyslipidemia
Grunfeld et al.
(1991)22
AIDS (n = 45); HIV+ (without
AIDS; n = 13); HIV−
(controls; n  = 17)
-  AIDS: ↑IFN- (p < 0.001 compared to controls); with detectable levels in 84%
of AIDS patients
-  HIV+: three of 13  had detectable IFN-
- AIDS and HIV+: signiﬁcant correlation between IFN- and  TG (R  = 0.44, p <  0.002)
IFN- modulated lipid metabolism, and was probably responsible for the
hypertriglyceridemia found in AIDS patients
Grunfeld et al.
(1989)1
AIDS (n = 32); HIV+ (n = 8);
HIV− (controls; n  = 17)
- AIDS versus controls: ↑TG and prevalence of  hypertriglyceridemia (50%)
(p <  0.002 and p < 0.005, respectively)
ART, antiretroviral therapy; CRP, C-reactive protein; HDL-c, high density lipoprotein; IFN-,  interferon-alpha; IL, interleukin; LDL-c, low density
lipoprotein; PURE, Prospective Urban and Rural Epidemiological study; TG,  triglycerides.
decrease, associated with insulin resistance, increase of
triglycerides  and reduction of HDL-c.29
Pregnancy already is a condition that is characterized by
important metabolic changes. The use of ART during preg-
nancy  is  associated with several concerns, which include
potential teratogenicity, risk for the exposed and uninfected
newborn, possible reduced efﬁcacy of antiretroviral regimens
in  this particular condition, and safety considerations for the
mother,  including potentially increased risk of speciﬁc adverse
events.6
HIV-infected older adults have a  slower immunological
response to  ART and a higher risk for cardiovascular diseases,
considering the factors: aging, HIV infection, and ART.7 A mul-
ticenter  cross-sectional study involving 179 elderly individuals
indicated that 54% had dyslipidemia, 23% had cardiovascular
diseases, and 58% had lipodystrophy.30
Six classes of antiretroviral drugs are currently available
(Table 2).
Protease inhibitors, NRTIs, and NNRTIs are  the drugs most
frequently associated with lipodystrophy and alterations in
lipid metabolism.32,33 Furthermore, the drugs of each class
exert  distinct metabolic effects.23
Table 3 summarizes the results of the original studies
(n  = 48) that assessed the  lipid proﬁle of HIV/AIDS patients with
ART.
Protease  inhibitors
Elevated plasma lipid concentrations were observed in 70%
to  80% of patients who received ART containing pro-
tease  inhibitors. This class of antiretroviral drugs has been
associated with the development of peripheral lipodys-
trophy, central adiposity, breast hypertrophy, and insulin
resistance.66,72–76
Patients who use protease inhibitors for a long period of
time  frequently present hypertriglyceridemia, elevated con-
centrations  of LDL-c, reduced HDL-c levels, and accumulation
of  apolipoprotein E  and apolipoprotein CIII (apoCIII).66,67,69,77
However, the reduction of HIV-1 viral load has been associated
with  an increase of serum HDL-c.69
In the ﬁrst exploratory studies, various protease inhibitors
(saquinavir, indinavir, nelﬁnavir, and ritonavir) were  associ-
ated  with different degrees of hyperlipidemia.71,78 However,
some authors found that dyslipidemic patients using pro-
tease  inhibitors who switched to atazanavir-containing
regimens showed improvement of lipid parameters, while the
immunological  and virological efﬁcacy of the regimen was
maintained.36,42,53,79–81
In a multicenter, prospective, observational study of 23,437
HIV-infected  patients conducted by the Data Collection on
Adverse Events of Anti-HIV Drugs (DAD) Study Group (2007), an
association was  initially observed between the  use of protease
Table 2 – Antiretroviral drugs by class.*
PI  NRTI  NNRTI FI CCR5 antagonist Integrase inhibitor
Atazanavir (ATV)
Darunavir  (DRV)
Fosamprenavir (FPV)
Indinavir  (IDV)
Lopinavir  (LPV)
Nelﬁnavir (NFV)
Ritonavir  (RTV)
Saquinavir  (SQV)
Tipranavir (TPV)
Abacavir (ABC)
Didanosine (ddI)
Emtricitabine (FTC)
Stavudine  (d4T)
Lamivudine  (3TC)
Tenofovir (TDF)
Zidovudine (AZT)
Efavirenz (EFV)
Etravirine  (ETR)
Nevirapine  (NVP)
Enfuvirtide
(T-20)
Maraviroc
(MVC)
Raltegravir  (RAL)
PI, protease inhibitors; NRTI, nucleoside reverse-transcriptase inhibitors; NNRTI, non-nucleoside reverse-transcriptase inhibitors; FI, fusion
inhibitor.
∗ Guidelines for the use of antiretroviral agents in HIV-1-infected adults  and adolescents.31
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Table 3 – Studies assessing the lipid proﬁle of patients with HIV/AIDS receiving ART.
Reference Type  of  ART Study  design and treatment duration Lipid proﬁle alterations
Podzamczer et al.
(2011)34
NVP versus ATZ/RTV, both
combined  with TDF + FTC
(ARTEN  Study)
Prospective  study  (n = 569): baseline evaluation
up  to 48  weeks
-  NVP promoted ↑  TC, ↑HDL-c, ↑LDL-c, and ↑apoA1, but not of  apoB; ATZ/r was
associated with ↑  TG; NVP versus ATZ/r: < TC/HDL-c ratio and < apoB/apoA ratio;
-  Low Framingham score in the  two  groups
MacInnes et al.
(2011)35
MVC  versus EFV Intervention  study: MVC  (n = 360) versus EFV
(n  = 361), both combined with AZT/3TC
for  96 weeks
-  For patients with TC and LDL-c below the  NCEP treatment thresholds at  the  beginning
of the study (TC: 35% × 11% in the  EFV group versus LDL-c: 23% × 8% in the MVC group)
(p  < 0.001)
-  For patients exceeding the  NCEP thresholds: TC: 83% × 50% (p = 0.008);  LDL-c: 86% ×
55% (p = 0.03); HDL-c: 43% × 62% (p = 0.002) (values referring to an increase for patients
with  HDL-c < 40  mg/dL)
Lu et al.  (2011)36 Two NRTI +ATV 1×/day
or  ATV/r 1×/day
Prospective  observational study (n =  66):
48  weeks
- ATV regimen was well tolerated and resulted in signiﬁcant improvement of
hyperlipidemia
Crane et al.
(2011)37
Comparison between NRTI
pairs  used in the  ﬁrst ART
Cohort  study (n = 2,267): patients with at least
two  months of ART
-  TDF/3TC or TDF/FTC associated with ↓  lipid levels (TC, TG, HDL-c, LDL-c and
non-HDL-c); ddI/3TC associated with ↑  LDL-c; d4T/3TC with ↑TG; ddI/d4T with ↑ HDL-c
Adewole et al.
(2010)25
NNRTI Cross-sectional study  (n = 130): 12  months - NNRTI containing NVP promoted ↑ HDL-c and stabilization of TC and TG
Battistini et al.
(2010)27
ART Cross-sectional study  with children and
adolescents (n =  30): median duration with ART:
28.4  months
-  Lipodystrophy: 53.3%
-  Dyslipidemia (AIDS versus controls): 60% versus 23% (p = 0.004)
- ↑  Frequency of dyslipidemia, lipodystrophy, and retinol and b-carotene deﬁciencies,
but  it was not  possible to demonstrate a correlation of  these ﬁndings with lipid
peroxidation
Randell et al.
(2010)38
TDF/3TC + FPV/RTV versus
TDF/3TC  + LPV/RTV
Intervention  study (n = 27): 2×/day
Pharmacokinetics was evaluated up
to two  weeks
- ↑  6.6%  TC  with FPV and 10.9% with LPV. Similar changes in lipids and lipoprotein
subfractions in the groups with ↑ TG, ↑VLDL, ↑chylomicrons and ↑LDL-c. No signiﬁcant
alteration in HDL-c and ↓  small-HDL-c
Palios et al.
(2010)39
HAART versus untreated Cross-sectional study  (n = 40)  - Patients on HAART presented ↑  TC compared to control
Nguemaïm et al.
(2010)18
ART Case-control study [HIV+ (n = 172) and HIV−
(n  = 172)]
HIV+ versus HIV- subjects:
-  CD4 < 50  cells/L: ↓TC and  ↓LDL-c (p < 0.0001); ↑TG (p < 0.001); > TC/HDL-c ratio
(p < 0.01); >  HDL-c/LDL-c ratio (p =  0.02)
- CD4 50–199 cells/L: ↓TC (p  < 0.001) and ↑TG (p < 0.001)
-  CD4 200–350 cells/L: ↑TG (p = 0.003); > TC/HDL-c (p < 0.0002); > HDL-c/LDL-c ratio
(p = 0.04)
- CD4 >350 cells/L: >  TC/HDL-c ratio (p <  0.0001); > HDL-c/LDL-c ratio (p < 0.001)
- HIV+: < HDL-c irrespective of  the  CD4  cell count.
Tungsiripat et al.
(2010)40
ART with TDF Double-blind, placebo-controlled crossover study
(n = 17): 12  weeks
TDF versus placebo:
-  ↓  non-HDL-c, ↓  LDL-c and ↓TC
-  TDF: lipid-lowering action
Werner et al.
(2010)28
HAART Cross-sectional study  with children
and  adolescents (n = 43): three months
-  Lipid abnormality: 88.3%;
-  Body shape change: 13.9%
Bunupuradah
et al.  (2009)41
Double-boosted PI
combination,  SQV and
LPV/r
n  =  50: 12  weeks (HIV-infected children who had
failed  on reverse transcriptase inhibitors)
-  TC and HDL-c ↑signiﬁcantly over time, whereas TG and LDL-c did not
-Body shape changes: Approximately 50%
Calza et al.
(2009)42
First HAART: ABC/3TC +
ATV/RTV  versus TDF/FTC +
ATV/RTV
Clinical Trial [ABC/3TC (n=42); TDF/FTC
(n=47)]:48 weeks
-  ABC/3TC + ATV/RTV: higher CD4
-  Both groups: ↓  TG. Similar TC  and LDL-c
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– Table 3  (Continued)
Reference Type of  ART Study design and treatment duration Lipid proﬁle alterations
Carosi et al.
(2009)43
ABC/3TC + FPV/RTV
(1400  mg/100 mg), 1×/day
versus ABC/3TC +  FPV/RTV
(700  mg/100 mg), 2×/day
Intervention study (n =  214): follow-up for 24
and  48  weeks
-  No signiﬁcant alteration in non-HDL-c values in either group
Kim et al. (2009)44 Different HAART regimens Single center, retrospective cohort study
(n = 178). (HIV-1 infected children with HAART
versus  HIV-1 infected children without
medications [controls])
-  72.4% had TC  > 180 mg/dl, 53.4% had TC >  200 mg/dl
- For TC > 200, the multivariable analysis showed ↑  risk  with NRTI/NNRTI (HR: 1.86, 95%
CI: 1.34–2.19) and NRTI/PI (HR: 3.45, 95% CI:  2.65–4.51) when compared to  controls
Sarni et al.
(2009)26
ART (80% HAART and  30%
with  PI)
Cross-sectional study with children
and adolescents (n = 30): median duration
with  ART = 28.4 months
-  Lipodystrophy: 53.3%
-  Dyslipidemia: 60%
-  Children on  HAART with PI:  > % of  mixed lipodystrophy
Tao et al. (2009)45 Comparison of patients on
HAART  with and without
lipodystrophy
Cross-sectional study (n = 52) -  Prevalence of  hypercholesterolemia, hypertriglyceridemia, and low HDL-c levels:
17.3%,  50.0%, and 17.3%, respectively
-  Patients with lipodystrophy: ↑  TG and ↓  HDL-c
Mothe et al.
(2009)30
HAART Multicenter cross-sectional study  with
HIV-1-infected population aged 70 years or more
(n = 179)
- Dyslipidemia: 54%
-Cardiovascular disease: 23%
-Lipodystrophy: 58%
Williams et al.
(2009)46
ART Prospective observational study (n = 433):
patients  received ART for  a mean of eight years
- 28% hypercholesterolemia
-  Patients receiving RTV or NNRTI (especially EFV) presented ↑  TC and TG
Estrada and
Fuster (2008)47
TDF+FTC+DRV/RTV versus
TDF+FTC+LPV/RTV
Intervention study: 48 weeks (ARTEMIS) - Similar virological and immunological response. DRV/RTV was associated with a
↓  frequency of  adverse lipid effects
Calza et al.
(2008)48
FPV/RTV versus LPV/RTV. Observational study  (n = 82): 18  months - LPV/RTV: ↑  TG
Farhi et al.
(2008)49
HAART Cross-sectional study (n = 235) - 77.5% prevalence of  dyslipidemia
Ananworanich
et al.  (2008)50
First HAART: two  NRTI  +
SQV/RTV
Intervention study (n =  272): 24  weeks - ↑  TC, ↑TG, ↑LDL-c, and ↑HDL-c
Pupulin et al.
(2008)51
HAART (68% with PI) Cross-sectional study (n = 60): use of  HAART
(mean:  ﬁve years)
-  ↑  TC (28%), ↑ HDL-c (83%), and ↑ LDL-c (3%) suggesting an  effect of  HIV  infection
and not of  HAART. 21% of patients with hypertriglyceridemia
Domingo et al.
(2008)52
Onset of  ART with two NRTI +
EFZ or two  NRTI + LPV/RTV
Retrospective cohort (VACH) (n = 1,550):
evaluation  at  zero to three; three to six; six to 12;
12-18; and >18 months
-  Use of LPV/RTV was associated with higher risk  of early hypertriglyceridemia
Bernal et al.
(2008)21
ART (NNRTI and PI) Cross-sectional (n =  219): two  months - Prevalence of  low HDL-c: 45%
Colaﬁgli et al.
(2008)53
AZT Observational study  (n = 197): follow-up
for  at  least  one month
-  AZT: ↓TC, ↓HDL-c, ↓non-HDL-c, and ↓TG.  Marked  reduction in patients with high
baseline TC and TG values. Decrease of cardiovascular risk
Kosalaraksa et al.
(2008)54
Double boosted PI,  SQV
and  LPV/r
n= 50:  48-weeks (children who have failed
NNRTI/NRTI- based regimens)
-  ↑  median TC and TG  (+ 35  mg/dL; + 37  mg/dL, respectively, p < 0.001)
Tassiopoulos
et al.  (2008)55
ART Prospective cohort study (Pediatric AIDS Clinical
Trials Group 219C) (n = 2,122 perinatally
HIV-infected children free of
hypercholesterolemia at  entry): six years
- 13% of  children had hypercholesterolemia at  entry
- + 13% developed hypercholesterolemia during follow-up for an incidence rate
of  3.4 cases per 100 person-years (95%  CI:  3.0-3.9)
- After adjustment for age, boosted PI use (HR: 13.9, 95% CI: 6.73-28.6), nonboosted PI
use  (HR: 8.65, 95% CI: 4.19-17.9), and NNRTI use (HR: 1.33,  95% CI:  1.04-1.71) were
associated with ↑  risk  of hypercholesterolemia, and > viral load was protective (> 50 000
versus ≤ 400 copies/mL; HR: 0.59, 95% CI: 0.39-0.90)
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Reference Type of  ART Study design and treatment duration Lipid proﬁle alterations
Aurpibul et al.
(2007)56
HAART (either NVP or EFV,
together  with 3TC  and d4T)
were  prospectively followed
n =  90  (Children): 144 weeks  -Central lipohypertrophy: 46%; peripheral lipoatrophy: 20%;  and combined type: 34%
-Hypertriglyceridemia: 12%; hypercholesterolemia: 11%
-Low HDL-c decreased from 94% at baseline to 12% at week 144 (p <  0.01)
Llibre et al.
(2006)20
Replacement of  d4T
with  TDF
Prospective  multicenter study (n = 873):
12  months
- ↓TC, ↓LDL-c and ↓TG. Patients with hyperlipidemia presented marked reduction
in LDL-c and TG. The greatest reduction in TG was observed in patients with severe
hypertriglyceridemia
Kumar et al.
(2006)57
ABC+3TC+AZT
versus AZT+3TC+NFV versus
d4T+3TC+NFV
Intervention  study: 96  weeks - ABC+3TC+AZT: lower LDL-c
-  TC: ABC+3TC+AZT<AZT+3TC+NFV< d4T+3TC+NF
- No change in HDL-c with any treatment
Castro-Sansores
et al.  (2006)58
HAART Cross-sectional  study  (n = 211) - 44% hyperlipidemia; 20% hypercholesterolemia; 32% hypertriglyceridemia;
14% hypertriglyceridemia + hypercholesterolemia; NRTI: more frequent lipid alterations
De Luca et al.
(2006)59
Onset  of  ART:
two  NRTI + EFV  versus two
NRTI  +  LPV/r
Prospective  observational cohort:
2  NRTI + EFV (n = 481); 2  NRTI  + LPV/r (n =  193)
- ART regimens containing EFV or LPV with similar efﬁcacy and tolerability
- LPV was associated with higher rates of hypertriglyceridemia
Floridia et al.
(2006)6
PI and  d4T use Observational study with HIV-infected pregnant
women (n = 248)
- ↑  mean lipid values progressively and signiﬁcantly during pregnancy: 141.6 mg/dL
for TG (p < 0.001), 60.8 mg/dL for TC (p < 0.001),  13.7 mg/dL for HDL-c (p < 0.001),
and 17.8 mg/dL for LDL-c  (p = 0.001)
- Women with PI versus without PI (at  all  trimesters): > mean TG
- d4T: dyslipidemic effect at  ﬁrst trimester only
Verkauskiene
et al.  (2006)29
HIV-infected children with
ART  (in the  majority of
children,  treatment was
>  four years)
Multicenter  study (n  = 130):  December 2000
to  April 2002
-  32 children with fat redistribution syndrome: 14 with atrophic lipodystrophy and 18
with  hypertrophic lipodystrophy
-  ↑  TG  and ↓ HDL-c in atrophic lipodystrophy versus no lipodystrophy
- HIV-infected children with symptoms of  fat redistribution: ↓adiponectin, associated
with  dyslipidemia
Jones et al.
(2005)60
First HAART using different
regimens:  two  NRTI +
one  NNRTI
versus two NRTI + one PI
versus  two NRTI + two PI
Prospective  longitudinal study (n = 1,664) -  d4T and PI associated with hypercholesterolemia
-  TDF+3TC+EFV (28 patients) without ↑TC
Keiser et al.
(2005)61
Two NRTI + one PI changing
to  two  NRTI  +  ABC versus
maintenance two NRTI +
one  PI
Evaluation  after 28  weeks: ABC (n = 52)  or PI
(n = 52)
- ABC: ↓  TC, ↓LDL-c, and ↓TG.  No  difference in HDL-c
Viganò et al.
(2005)62
Patients receiving HAART
containing  3TC, d4T and a
PI  were randomized to
switch  PI to EFV  and  d4T
to  TDF at baseline (Group 1)
or  at  week 24 (Group 2)
Prospective  evaluation (n = 28: 48-weeks;
HIV-infected children)
-  Group 1: signiﬁcant ↓  in cholesterol (p < 0.05), ↓  HDL-c ratio (p < 0.01), and ↓TG (p <
0.05)  was observed 24 and 48  weeks after the switch of HAART
-Group 2: unchanged lipids in 24  weeks  prior to the switch of  HAART and a  signiﬁcant
improvement on cholesterol (p < 0.05), HDL-c ratio (p < 0.01), and TG  (p < 0.05) were
observed 24 weeks after the switch of  HAART
Lucas et  al.
(2003)63
HAART Cohort study (n = 444):  ﬁve years - After four years, 35% of  the patients with viral suppression developed diabetes
and hyperlipidemia
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Christeff et al.
(2002)64
ART Cross-sectional study  (n = 42; 27  of whom had
symptoms  of  lipodystrophy)
-  ↑IFN- in lipodystrophy-positive versus lipodystrophy-negative and controls
- ↑IFN-: positive correlation with ↑TC, ↑TG,  ↑VLDL, ↑  apoB and >apoB/apoAI ratio
Galli et al.
(2002)65
Two NRTIs Follow-up for three months (n = 335) - 23%: hypertriglyceridemia
-  10.5%: hypercholesterolemia
Fauvel et al.
(2001)66
PI with two NRTIs (most
frequently:  IDV with d4T
and  3TC)
Follow-up  for three months (n = 60 male) - Carriers of  the -455C variant: 30% lower levels of HDL-c than non-carriers. TG↑
according to the number of variant alleles
- Apo C-III polymorphisms: genetic predisposition to develop dyslipidemia under PI
therapy
Rakotoambinina
et al.  (2001)67
HAART with PI Cohort (n = 175): 24 months - Lipoatrophy: ↑TG
-  Nucleoside analog: risk  factor for lipoatrophy
Thiébaut et al.
(2001)68
HAART (PI versus other
HAART  combinations)
Prospective  cohort (n = 925): 25 months - 70 experienced hypertriglyceridemia; 4.2 cases per 100 person years (CI=3.2 ±5.2)
-  Baseline TG level and being overweight were risk factors of hypertriglyceridemia,
together with advanced HIV  disease. The contribution of  HAART was not  demonstrated
Vergis et al.
(2001)69
ART with PI Prospective study  (n = 56): one year - ↑TG (> 250 mg/dL): 52%
- Adherence >  80% to a PI versus adherence < 80%:  ↑LDL-c (79%); severe ↑TG
(> 800 mg/dL) (21%)
- < Viral load was associated with > HDL-c level
Carr et al.
(1999)70
ART with PI versus ART
without  PI
With  PI (n = 113): follow-up mean 21  months
Never  treated with PI (n = 45; 28 with follow-up)
-  Lipodystrophy: 83% of  PI recipients and 4% of treatment-naïve patients (p = 0.0001)
- < Body fat: independently associated with longer duration of PI therapy and
<  bodyweight before therapy, and  more severe lipodystrophy was associated with ↑TG
and  ↑C-peptide (previous [p  < 0.03]  and current [p ≤  0.01], and less peripheral
and greater central fat [p = 0.005 and  0.09; respectively])
-  Hyperlipidemia: 74% of  treated patients versus 28% of naïve patients (p<0.001)
Schmidt et al.
(1999)71
PI-treated patients versus
control  group
Prospective  study  (n = 98)  - 57%: Hyperlipidemia
-  PI-treated patients versus control group: LDL-c=146 mg/dL (range: 53-274 mg/dL) versus
105 mg/dL (range: 22-188 mg/dL; p < 0.001); VLDL = .5 mg/dL (5-253 mg/dL) versus
18 mg/dL (range: 3-94 mg/dL; p < .001)
- > Frequency of  the  apolipoprotein E2 allele and E4 allele: hyperlipidemic subjects
- Patients with excessive hypertriglyceridemia: ↓  lipoprotein lipase activity
-  >Lipodystrophy: hyperlipidemic
ABC, abacavir; APV, amprenavir; ART, antiretroviral therapy; ATV, atazanavir; AZT, zidovudine; 95% CI, 95% conﬁdence interval; DRV, darunavir; ddI,  didanosine; d4T, stavudine; EFV,  efavirenz; ETR,
etravirine; FPV, fosamprenavir; FTC, emtricitabine; HAART, highly active antiretroviral therapy; HR, hazard ratio; HDL-c, high density lipoprotein; IDV,  indinavir;IL, interleukin; IFN-,  interferon alpha;
LDL-c, low density  lipoprotein; LPV, lopinavir; LPV/r, lopinavir with a  booster of  ritonavir; MVC, maraviroc; NCEP, National Cholesterol Education Program; NFV, nelﬁnavir; NNRTI, non-nucleoside reverse
transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; NVP, nevirapine; PI,  protease inhibitor; RTV, ritonavir; SQV,  saquinavir; TC, total cholesterol; TDF, tenofovir; TG,  triglycerides;
TNF-, tumor necrosis factor alpha; TPV, tipranavir; 3TC, lamivudine.
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inhibitors and an increased risk of myocardial infarction. How-
ever,  this risk was  slightly lower after adjustment for lipid
concentrations.82 In a  subsequent investigation by the DAD
Study  Group, the best model to predict the risk of myocar-
dial  infarction derived from a  dataset of 22,625 HIV-infected
patients without a  history of cardiovascular disease should
include  age, gender, systolic blood pressure, smoking status,
family  history of cardiovascular diseases, diagnosis of dia-
betes,  total cholesterol, HDL-c, time of indinavir and lopinavir
exposure, and current use of abacavir.83
The Pediatric AIDS Clinical Trials Group 219C was the ﬁrst
large  prospective cohort study to  examine the effect of pro-
tease  inhibitors and other antiretroviral medications on the
incidence  of hypercholesterolemia among HIV-infected chil-
dren  and adolescents. This group indicated that the use of
protease  inhibitors leads to a  marked increase in total choles-
terol  levels.55
Kim et al.,  in  a  retrospective cohort study involving HIV-
1  infected children with highly active antiretroviral therapy
(HAART)  versus HIV-1 infected children without HAART found
that  those using the NRTI/protease inhibitors-regimen pre-
sented signiﬁcantly higher total cholesterol levels than NRTI
and  NRTI/NNRTI.44
For children who have failed on reverse transcrip-
tase inhibitors-based regimens, double boosted protease
inhibitors, saquinavir, lopinavir, and ritonavir represents an
option for second line treatment. However, the drugs signiﬁ-
cantly  increased the  median levels of serum cholesterol and
triglycerides  after 48 weeks.54 Bunupuradah et al., in the same
population,  showed that, after 12 weeks, total cholesterol and
HDL-c  increased signiﬁcantly, whereas triglycerides and LDL-c
did  not.41
In an observational study with HIV-infected pregnant
women, there were differences in  lipid values at each
trimester by protease inhibitors and stavudine use. HIV-
positive pregnant women using protease inhibitors presented
a  progressive increase in triglycerides and cholesterol values
from  the ﬁrst to the third trimester.6
Nucleoside  reverse-transcriptase  inhibitors
Antiretroviral treatment regimens containing NRTIs have
also  been associated with alterations in body fat deposition,
particularly lipoatrophy, similar to the alterations observed
with  protease inhibitor-containing regimens. In addition,
metabolic alterations, particularly changes in serum triglyc-
eride  concentrations, are observed.65
However, the alterations in lipid metabolism are less evi-
dent  in patients using a  combination of tenofovir + lamivudine
compared to those using zidovudine + lamivudine, stavudine +
lamivudine, or didanosine + lamivudine, with the observation
of  lower serum concentrations of LDL-c, total cholesterol, and
triglycerides  in the former.37,40
The effect of regimens containing tenofovir indicates a
lipid-lowering action of this NRTI and differs from that of
other  drugs from the same class of antiretroviral drugs.37,40,53
Replacement of NRTIs such as  stavudine with tenofovir might
be  a useful strategy to improve the  lipid proﬁle of patients
with  dyslipidemia, particularly triglyceride levels, with a  con-
sequent  reduction of cardiovascular risk.20 For HIV-infected
children, switching stavudine to tenofovir is  virologically and
immunologically safe and provides a signiﬁcant improvement
in  lipid proﬁle.62
In contrast, the  use of the NRTIs abacavir and didanosine
was  found to be an independent risk factor for myocar-
dial  infarction in the DAD Study.84 Subsequently, the same
group  found that current use of abacavir was an independent
risk  factor for myocardial infarction above the measurable
metabolic effects of the  drug.83
Floridia et  al. showed that stavudine was  associated with
dyslipidemic effect in HIV-infected pregnant women  in the
ﬁrst  trimester only.6
Non-nucleoside  reverse-transcriptase  inhibitors
ART regimens containing nevirapine are associated with a bet-
ter lipid proﬁle, mainly because they provide higher serum
concentrations of HDL-c.34,85,86 Bernal et  al. observed that an
undetectable viral load and NNRTI regimens containing nevi-
rapine  protected against low levels of HDL-c.21
The lipid proﬁle of patients with AIDS and a  previous
history of severe immunodepression who achieved immune
reconstitution with ART has been shown to  vary according to
the antiretroviral regimen used. Patients treated with protease
inhibitors (booster dose of ritonavir) or efavirenz presented
a  signiﬁcant increase of total cholesterol and triglyceride
concentrations, whereas an  increase of serum HDL-c levels
was  observed in those receiving nevirapine.46 However, for
HIV-infected children, Viganò et  al. demonstrated that switch-
ing  the protease inhibitor to efavirenz improved the lipid
proﬁle.62
Aurpibul et  al. showed that, in HIV-infected children who
began  HAART (either nevirapine or efavirenz, together with
lamivudine and stavudine), low HDL-c decreased from 94% at
baseline to  12% at week 144 (p < 0.01); dyslipidemia occurred
only  in 11% to 12% of children.56
Possible  metabolic  mechanisms
Protease inhibitors are known to inhibit lipogenesis and
adipocyte  differentiation and to stimulate lipolysis of subcu-
taneous  fat. NRTIs, in turn, can also reduce lipogenesis and
adipocyte  differentiation in subcutaneous tissue and might be
one of the possible causes of mitochondrial toxicity, inhibiting
mitochondrial DNA polymerase , which leads to the deple-
tion  of mitochondrial DNA. In addition, antiretroviral drugs
have  been shown to increase central visceral fat and the lev-
els  of fatty acids in blood, with a further increase of fatty acids
oxidation.23,64
Apparently, HIV/AIDS patients receiving ART who  develop
lipodystrophy have higher serum concentrations of inﬂamma-
tory  cytokines (IL-6 and TNF-). In addition, evidence indicates
a  relationship between an increase of IFN-  and  elevations of
serum  concentrations of total cholesterol, triglycerides, VLDL,
apoB,  and apoB/apoA1.64 In this respect, protease inhibitors
appear to  bind to LDL receptor-related protein (LRP), reducing
the  cleavage of fatty acids from circulating triglycerides by the
LRP-lipoprotein  lipase complex on vascular endothelium, and
impairing  the uptake of remnant hepatic chylomicrons and
VLDL.76,87 Moreover, protease inhibitors may  directly stimu-
late  hepatic triglyceride synthesis through up-regulation of
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mRNA  production in hepatic cells for key enzymes involved in
the triglyceride biosynthetic pathway, leading to  the hepatic
accumulation of triglyceride-rich lipoparticles.77
These drugs may  also modify lipoprotein metabolism by
interfering with the expression of inﬂammatory cytokine
genes  and oxidative stress-related genes.87 The expression
of  genes in adipocytes and hepatocytes is modulated by pro-
tease  inhibitors through sterol regulatory element-binding
proteins (SREBPs), cytoplasmic retinoic-acid binding protein
type  1 (CRABP-1), peroxisome proliferator activated receptors
(PPARs),  and apoCIII, events that contribute to the develop-
ment  of atherogenic dyslipidemia.3
Carr et al. have proposed that the  pathogenesis of lipodys-
trophy  syndrome is based upon the structural similarity
between the catalytic region of HIV-1 protease and CRABP-
1  and LRP, probably establishing a high afﬁnity among these
elements.76
Protease inhibitor-induced peripheral lipodystrophy is  a
result  of impaired CRABP1-mediated cis-9-retinoic acid stim-
ulation  of retinoid X  receptor: PPAR- and of the capacity of
protease  inhibitors to inhibit cytochrome P450 3A, resulting
in  reduced differentiation and increased apoptosis of periph-
eral  adipocytes. Hyperlipidemia is exacerbated by inhibition
of  LRP, leading to central obesity, breast fat deposition in the
presence  of estrogen, insulin resistance, and diabetes mellitus
type  2.76
Bastard et al. found that protease inhibitors induce altered
differentiation status of peripheral adipocytes by altering
SREBP1  function in vivo, because this abnormal adipocyte
differentiation is associated with greatly reduced SREBP1c
expression. 88
Nevertheless, the mechanisms that promote lipid alter-
ations  in HIV/AIDS patients are still not completely under-
stood,  and may  be potentiated by genetic and environmental
factors, as well as  by medications.23
Conclusions
HIV-infected patients without ART presented lipid alter-
ations  associated with the infection itself, characterized
by a  decrease of total cholesterol, LDL-c, and HDL-c,
and by an  increase of triglyceride levels. In contrast,
ART regimens promoted distinct alterations in the lipid
metabolism of these patients. Protease inhibitors, particu-
larly  indinavir and lopinavir, were commonly associated with
hypercholesterolemia, hypertriglyceridemia, elevated LDL-c,
and  reduced HDL-c. Fewer lipid alterations were observed
with  use of the protease inhibitor atazanavir. Some NRTIs
(didanosine, stavudine, and zidovudine) more  frequently
induced lipid alterations, particularly lipoatrophy and hyper-
triglyceridemia. However, tenofovir-containing NRTI regimens
resulted  in  a better metabolic proﬁle. Patients using NNRTIs
developed hypertriglyceridemia and hypercholesterolemia.
The NNRTI nevirapine was  particularly associated with ele-
vated  concentrations of HDL-c. Therefore, the infection itself,
the  different classes of drugs, and some drugs from the
same class of ART appear to  exert distinct alterations in  lipid
metabolism.
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